Increased Body Mass Index Is Associated with Earlier Time to Loss of Response to Infliximab in Patients with Inflammatory Bowel Disease

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Inflammatory Bowel Diseases

• Publication date

  2013-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MIB.0b013e31829cf401PMID 23863401
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients

  2012cited by this paper
• Differences between Adiposity Indicators for Predicting All-Cause Mortality in a Representative Sample of United States Non-Elderly Adults

  2012cited by this paper
• Direct Medical Cost of Managing IBD Patients: A Canadian Population‐based Study

  2012cited by this paper
• Body mass index and clinical response to infliximab in rheumatoid arthritis.

  2011cited by this paper
• Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

  2011cited by this paper
• Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease 12

  2011cited by this paper
• Top-down therapy for IBD: rationale and requisite evidence

  2010cited by this paper
• Association between adiposity in midlife and older age and risk of diabetes in older adults.

  2010cited by this paper
• Infliximab, azathioprine, or combination therapy for Crohn's disease.

  2010cited by this paper
• The Placebo Response Rate in Irritable Bowel Syndrome and Inflammatory Bowel Disease

  2010cited by this paper
• Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease

  2009cited by this paper
• Effect of anti-tumor necrosis factor-therapies on body mass index in patients with psoriasis

  2008cited by this paper
• Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort

  2008cited by this paper
• Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis.

  2008cited by this paper
• Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes.

  2007cited by this paper
• EDITOR’S QUIZ: GI SNAPSHOT

  2007cited by this paper
• Clinical Pharmacokinetics and Use of Infliximab

  2007cited by this paper
• The impact of increased body mass index on the clinical course of Crohn's disease.

  2006cited by this paper
• Infliximab for induction and maintenance therapy for ulcerative colitis.

  2005cited by this paper
• Infliximab maintenance therapy for fistulizing Crohn's disease.

  2004cited by this paper
• An analysis of factors influencing short‐term and sustained response to infliximab treatment for Crohn's disease

  2003cited by this paper
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

  2002cited by this paper
• High serum tumor necrosis factor-α levels are associated with lack of response to infliximab in fistulizing Crohn's disease

  2002cited by this paper
• Predictors of response to infliximab in patients with Crohn's disease.

  2002cited by this paper
• Crohn's disease clinical course and severity in obese patients.

  2002cited by this paper
• Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease

  2002cited by this paper
• Infliximab for the treatment of fistulas in patients with Crohn's disease.

  1999cited by this paper
• Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.

  1995cited by this paper
• Juvenile onset inflammatory bowel disease: height and body mass index in adult life

  1994cited by this paper
• Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha.

  1994cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Diet and Gut Microbiota in Inflammatory Bowel Disease: A Clinical and Nutritional Perspective.

  2026cites this paper
• Body Mass Index Did Not Affect Efficacy and Safety of Etrasimod: A Post Hoc Analysis of the ELEVATE Ulcerative Colitis Clinical Program

  2025cites this paper
• Tolerability and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Inflammatory Bowel Disease

  2025cites this paper
• Unravelling the Relationship Between Obesity and Inflammatory Bowel Disease

  2025cites this paper
• Mortality risk associated with general and central obesity in inflammatory bowel disease patients: a long-term prospective cohort study

  2025cites this paper
• Sub-cutaneous infliximab for perianal Crohn's disease: the BioLap-Rem multicentre study from the GETAID.

  2025cites this paper
• Body mass index does not influence loss of response to tumor necrosis factor inhibitors in Crohn's disease.

  2025cites this paper
• Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Inflammatory Bowel Disease.

  2025cites this paper
• Serum infliximab concentrations and body mass index in patients with inflammatory bowel disease.

  2025cites this paper
• Epidemiology of metabolic syndrome in patients with inflammatory bowel disease: a population-level cohort study from the United States

  2025cites this paper
• Therapeutic Drug Monitoring in Special Circumstances in Inflammatory Bowel Disease

  2025cites this paper
• Long-Term Outcomes and Therapeutic Strategies for Newly Diagnosed Crohn’s Disease in the Biologic Era: A Nationwide Claims-Based Study from Japan

  2025influential citation
• Vitamin D enhances the therapeutic effect of TNF-α antibodies through lipid metabolism in overweight IBD patients

  2025cites this paper
• Validation of prediction models for anti-tumor necrosis factor treatment response in pediatric Crohn's disease: a systematic review and prospective cohort study.

  2025cites this paper
• A High Visceral-to-Skeletal Muscle Area Ratio on Cross-Sectional Imaging Is Associated With Failure of Standard Ustekinumab Doses: A Multicenter Study

  2024cites this paper
• High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn’s Disease

  2024cites this paper
• Prevalence of Metabolic Syndrome and Its Association with Cardiovascular Outcomes in Hospitalized Patients with Inflammatory Bowel Disease

  2024cites this paper
• CT-based body composition parameters predict the loss of response to infliximab in patients with Crohn's disease.

  2024cites this paper
• TNF compromises intestinal bile-acid tolerance dictating colitis progression and limited infliximab response.

  2024cites this paper
• Paediatric obesity and Crohn's disease: a descriptive review of disease phenotype and clinical course.

  2024cites this paper
• Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.

  2024cites this paper
• Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease

  2023cites this paper
• Trajectory of body mass index and obesity in children with Crohn's disease compared to healthy children.

  2023cites this paper
• The impact of bariatric surgery on admissions for gastrointestinal complications and conditions associated with obesity: A nationwide study.

  2023cites this paper
• The Impact of Obesity on Inflammatory Bowel Disease

  2023cites this paper
• Body Mass Index Profile of Adult Patients with Inflammatory Bowel Disease in a Multicenter Study in Northeastern Brazil

  2023cites this paper
• Biologics and the Timing of Operative Management of Pediatric Inflammatory Bowel Disease

  2023cites this paper
• The importance of predicting patient responses to monoclonal antibodies for Crohn’s disease

  2023cites this paper
• Serum Ɣ-Globulins Predictive Value on Anti- TNFα Response among Children with Inflammatory Bowel Disease

  2023cites this paper
• Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD

  2023cites this paper
• A review of the role of intermittent fasting in the management of inflammatory bowel disease

  2023cites this paper
• Practical guideline on obesity care in patients with gastrointestinal and liver diseases - Joint ESPEN/UEG guideline.

  2023cites this paper
• Obesity and novel management of inflammatory bowel disease

  2023cites this paper
• Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis

  2023cites this paper
• Impact of tumor necrosis factor antagonist combination and anti-integrin therapies on body mass index in inflammatory bowel disease: A cross-sectional study

  2023cites this paper
• Influence of biologic therapy on cardiovascular risk factors in patients with inflammatory bowel disease

  2023cites this paper
• Impact of Obesity on Response to Biologic Therapies in Patients with Inflammatory Bowel Diseases

  2022cites this paper
• Influence of obesity on the course of inflammatory bowel disease

  2022cites this paper
• Obesity, a challenge in the management of inflammatory bowel diseases

  2022cites this paper
• European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint ESPEN/UEG guideline.

  2022cites this paper
• European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline

  2022cites this paper
• High-fat diet aggravates colitis via mesenteric adipose tissue derived exosome metastasis-associated lung adenocarcinoma transcript 1

  2022cites this paper
• Systematic review and meta-analysis: association between obesity/overweight and surgical complications in IBD

  2022cites this paper
• Effect of obesity on vedolizumab response in inflammatory bowel disease

  2022cites this paper
• "Influence of biologic therapy on cardiovascular risk factors in patients with inflammatory bowel disease".

  2022cites this paper
• Predictor of primary response to antitumor necrosis factor-α therapy for inflammatory bowel disease: a single-center observational study

  2022cites this paper
• Inflammatory Bowel Diseases: Is There a Role for Nutritional Suggestions?

  2021cites this paper
• Infliximab vs. Ustekinumab in Biologic Naive Crohn's Disease.

  2021cites this paper
• Physical Activity in Patients With Inflammatory Bowel Disease: A Narrative Review.

  2021cites this paper
• Changing phenotype of inflammatory bowel disease and neglected metabolic health

  2021cites this paper
• A Novel Radiomics Nomogram for the Prediction of Secondary Loss of Response to Infliximab in Crohn’s Disease

  2021cites this paper
• Obesity in inflammatory bowel disease: A review of its role in the pathogenesis, natural history, and treatment of IBD

  2021cites this paper
• The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme

  2021cites this paper
• Limited long‐term treatment persistence of first anti‐TNF therapy in 538 patients with inflammatory bowel diseases: a 20‐year real‐world study

  2021cites this paper
• Infliximab vs. Ustekinumab in Biologic Naive Crohn's Disease.

  2021cites this paper
• Does Chronic Intestinal Inflammation Promote Atrial Fibrillation: A Mendelian Randomization Study With Populations of European Ancestry

  2021cites this paper
• Predictive value of bowel ultrasound in Crohn's disease.

  2021cites this paper
• Role of Adipose Tissue in Inflammatory Bowel Disease

  2021cites this paper
• Nutrition in the Management of Inflammatory Bowel Diseases.

  2021cites this paper
• Changing Patterns of Relationships Between Geographic Markers and IBD: Possible Intrusion of Obesity

  2020cites this paper
• BMI in the lower and upper quartiles at diagnosis and at 1-year follow-up is significantly associated with higher risk of disease exacerbation in pediatric inflammatory bowel disease

  2020cites this paper
• Rising Rate of Obesity in Patients Admitted for Crohn’s Disease Increases Costs But Not Mortality

  2020cites this paper
• Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study

  2020cites this paper
• Choosing the most appropriate biologic therapy for Crohn’s disease according to concomitant extra-intestinal manifestations, comorbidities, or physiologic conditions

  2020cites this paper
• Patient’s profiling for therapeutic management of inflammatory bowel disease: a tailored approach

  2020cites this paper
• Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases

  2020cites this paper
• Body Composition Using Air Displacement Plethysmography in Children With Inflammatory Bowel Disease.

  2020cites this paper
• Associations Between Obesity and the Effectiveness of Anti–Tumor Necrosis Factor-α Agents in Inflammatory Bowel Disease Patients: A Literature Review and Meta-analysis

  2020cites this paper
• Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn's Disease: A Post Hoc Analysis of the IM-UNITI Trial.

  2020cites this paper
• Impact of Obesity on the Management of Inflammatory Bowel Disease.

  2020cites this paper
• Genotype-based Treatment With Thiopurine Reduces Incidence of Myelosuppression in Patients With Inflammatory Bowel Diseases.

  2020cites this paper
• Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease

  2020cites this paper
• Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab.

  2020cites this paper
• Inflammatory bowel disease and the risk for cardiovascular disease: Does all inflammation lead to heart disease?

  2020cites this paper
• Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments

  2020cites this paper
• Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease.

  2019cites this paper
• Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.

  2019cites this paper
• ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases

  2019cites this paper
• Effects of obesity on the course of inflammatory bowel disease

  2019cites this paper
• Obesity in Autoimmune Diseases

  2019cites this paper
• A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease

  2019cites this paper
• Influence de l’obésité sur l’efficacité de différents agents biologiques dans les maladies inflammatoires : revue systématique et méta-analyse

  2019cites this paper
• Systematic review of nutrition screening and assessment in inflammatory bowel disease

  2019cites this paper
• Thanks ! Title The changing phenotype of Inflammatory Bowel Disease

  2019cites this paper
• Relationship(s) between obesity and inflammatory bowel diseases: possible intertwined pathogenic mechanisms

  2019cites this paper
• Bariatric Surgery and Crohn’s Disease

  2019cites this paper
• Is Bariatric Surgery Safe and Effective in Patients with Inflammatory Bowel Disease?

  2019cites this paper
• Long-Term Prognosis of Japanese Patients with Crohn’s Disease Treated by Switching Anti-Tumor Necrosis Factor-α Antibodies

  2019cites this paper
• High body mass index is not associated with increased treatment failure in infliximab treated pediatric patients with inflammatory bowel disease

  2019cites this paper
• Treatment Failure of TNF-α Inhibitors in Obese Patients With Inflammatory Bowel Disease-A Cohort Study.

  2018cites this paper
• Differences in adiposity and diet quality among individuals with inflammatory bowel disease in Eastern Canada

  2018cites this paper
• Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials

  2018cites this paper
• Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis

  2018cites this paper
• Obesity and inflammatory bowel disease: diagnostic and therapeutic implications

  2018cites this paper
• How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease

  2018cites this paper
• Long-term prognosis of Japanese patients with biologic-naïve Crohn’s disease treated with anti-tumor necrosis factor-α antibodies

  2018cites this paper
• Bariatric Therapy

  2018cites this paper
• Endoscopists and Surgeons Playing in the Same Team: The Multidisciplinary Approach in Screening and Preoperative Workup

  2018cites this paper
• High and low body mass index may predict severe disease course in children with inflammatory bowel disease

  2018cites this paper
• High body mass index is associated with increased risk of treatment failure and surgery in biologic‐treated patients with ulcerative colitis

  2018influential citation